Investigation of satisfaction and efficacy after switching from daily DPP-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes -prospective observational study-
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Trelagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 31 Jul 2017 Planned number of patients changed from 240 to 211.
- 31 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2017 Planned End Date changed from 31 Dec 2017 to 31 Oct 2017.